Health science solutions provider Revvity Inc (NYSE: RVTY) announced on Monday that it has entered a strategic collaboration with life science company Element Biosciences Inc to commercialise an in vitro diagnostic (IVD) workflow for neonatal sequencing.
This partnership builds on Revvity's introduction of an automated next-generation sequencing (NGS) workflow for newborn research and supports Element's progress toward regulatory approval of its AVITI sequencing system.
The collaboration will co-develop a comprehensive IVD solution for newborn sequencing, while providing immediate access to a research-use-only (RUO) version of the workflow. The IVD solution will enhance both Element's AVITI sequencing system and Revvity's sequencing workflow, which includes sample collection devices, nucleic acid extractors, NGS preparation kits and software for data analysis.
Revvity, with over USD2.7bn in revenue for 2023, serves customers across pharmaceutical, biotech, diagnostic labs, academia and governments.
Element Biosciences focuses on providing affordable, high-quality sequencing tools for research markets.
Sanofi and J&J discontinue phase 3 study of E. coli vaccine candidate
OnCusp Therapeutics' CUSP06 receives US FDA Fast Track Designation
MimiVax reports positive interim analysis of SurVaxM Phase 2b clinical trial
Akeso enrols first patient in cadonilimab Phase 3 clinical trial
NKGen Biotech receives US FDA Fast Track designation for troculeucel in Alzheimer's treatment
Neuphoria Therapeutics to receive USD15m milestone payment from Merck
TriNetX and Fujitsu form joint venture to enhance clinical research in Japan
Royalty Pharma to invest up to USD250m in Biogen's lupus treatment
Lundbeck receives FDA Fast Track designation for amlenetug in multiple system atrophy
Lytix Biopharma secures US patent allowance for LTX-315 clinical programme
GenSight Biologics reports positive five-year resultsfor LUMEVOQ gene therapy
IXICO's AI platform validated in Huntington's Disease research
ILIKOS Consulting partners with Jordan Center for Pharmaceutical Research
Spinogenix reveals topline results from Phase 2 study in Fragile X syndrome
Moleculin's Phase 3 R/R AML pivotal trial receives first European country recruitment approval